[go: up one dir, main page]

DE809996T1 - Interferon-Konjugate - Google Patents

Interferon-Konjugate

Info

Publication number
DE809996T1
DE809996T1 DE0809996T DE97108261T DE809996T1 DE 809996 T1 DE809996 T1 DE 809996T1 DE 0809996 T DE0809996 T DE 0809996T DE 97108261 T DE97108261 T DE 97108261T DE 809996 T1 DE809996 T1 DE 809996T1
Authority
DE
Germany
Prior art keywords
conjugate
ifna
peg
daltons
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE0809996T
Other languages
English (en)
Other versions
DE19708261A1 (de
DE19708261B4 (de
Inventor
Pascal Sebastian Bailon
Alicia Vallejo Palleroni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21790006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE809996(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE809996T1 publication Critical patent/DE809996T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (14)

  1. Patentansprüche
    Il
    O
    worin R und R' unabhängig Niederalkyl sind; X NH oder O ist; &eegr; und n' ganze Zahlen mit einer Summe von 600 bis 1.500 sind und das durchschnittliche Molekulargewicht der Polyethylenglycoleinheiten in dem Konjugat von etwa 26.000 Dalton bis etwa 66.000 Dalton ist.
  2. 2. Konjugat nach Anspruch 1, worin das Molekulargewicht der Polyethylenglycoleinheiten von etwa 35.000 bis etwa 45.000 Dalton ist.
  3. 3. Konjugat nach Anspruch 2, worin das Molekulargewicht der Polyethylenglycoleinheiten etwa 40.000 Dalton ist.
  4. 4. Konjugat nach Anspruch 1, worin R und R' Methyl sind.
  5. 5. Konjugat nach Anspruch 1, worin X NH ist.
  6. 6. Konjugat nach Anspruch 1, worin das IFNa IFNa2a ist.
  7. 7. Konjugat nach Anspruch 1, worin die mittlere Summe von &eegr; und n' 850 bis 1.000 ist.
  8. 8. Konjugat nach Anspruch 1, worin R und R' Methyl sind; X NH ist; IFNa IFNa2a ist und eine oder beide von &eegr; und n' 420 ist.
  9. 9. Konjugat nach Anspruch 1, worin R und R' Methyl sind; X NH ist; IFNa IFNa2a ist und eine oder beide von &eegr; und n' 520 ist.
  10. 10. Konjugat nach Anspruch 1, das eine größere antiproliferative Aktivität als IFNa hat und eine geringere antivirale Aktivität als IFNa.
  11. 11. Verfahren zur Herstellung eines PEG-IFNa-Konjugats mit einer erhöhten antiproliferativen Aktivität und einer erniedrigten antiviralen Aktivität verglichen mit IFNa, wobei das Verfahren aus dem kovalenten Anbinden eines Reagenzes der Formel II an IFNa zur Herstellung des PEG-IFNa-Konjugats besteht.
  12. 12. Pharmazeutische Zusammensetzung, umfassend ein PEG-IFNa-Konjugat wie in einem der Ansprüche 1-10 beansprucht und einen therapeutisch inerten Träger.
  13. 13. Pharmazeutische Zusammensetzung zur Behandlung oder Prophylaxe von immunmodulatorischen Erkrankungen wie neoplastischen Erkrankungen oder infektiösen Erkrankungen, umfassend ein PEG-IFNa-Konjugat wie in einem der Ansprüche 1-10 beansprucht und einen therapeutisch inerten Träger.
  14. 14. "Verwendung eines PEG-IFNa-Konjugats nach einem der Ansprüche 1-10 zur Herstellung eines Medikaments für eine Verwendung in der Behandlung oder Prophylaxe von Erkrankungen.
DE0809996T 1996-05-31 1997-05-22 Interferon-Konjugate Pending DE809996T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1883496P 1996-05-31 1996-05-31

Publications (1)

Publication Number Publication Date
DE809996T1 true DE809996T1 (de) 1998-04-09

Family

ID=21790006

Family Applications (3)

Application Number Title Priority Date Filing Date
DE2003199018 Pending DE10399018I1 (de) 1996-05-31 1997-05-22 Interferon-Konjugate
DE69720320T Expired - Lifetime DE69720320T2 (de) 1996-05-31 1997-05-22 Interferon-Konjugate
DE0809996T Pending DE809996T1 (de) 1996-05-31 1997-05-22 Interferon-Konjugate

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE2003199018 Pending DE10399018I1 (de) 1996-05-31 1997-05-22 Interferon-Konjugate
DE69720320T Expired - Lifetime DE69720320T2 (de) 1996-05-31 1997-05-22 Interferon-Konjugate

Country Status (48)

Country Link
US (1) US7201897B2 (de)
EP (1) EP0809996B1 (de)
JP (1) JP2980569B2 (de)
KR (1) KR100254097B1 (de)
CN (1) CN1088721C (de)
AR (1) AR008378A1 (de)
AT (1) ATE235920T1 (de)
AU (1) AU725195B2 (de)
BG (1) BG62273B1 (de)
BR (1) BR9703421A (de)
CA (1) CA2203480C (de)
CO (1) CO4950528A1 (de)
CY (2) CY2433B1 (de)
CZ (1) CZ292775B6 (de)
DE (3) DE10399018I1 (de)
DK (1) DK0809996T3 (de)
EG (1) EG24292A (de)
ES (1) ES2110386T3 (de)
GR (1) GR970300063T1 (de)
HK (1) HK1005225A1 (de)
HR (1) HRP970298B1 (de)
HU (1) HU227992B1 (de)
IL (1) IL120902A (de)
IS (1) IS1988B (de)
LU (1) LU91029I2 (de)
MA (1) MA24193A1 (de)
MY (1) MY117909A (de)
NL (1) NL300127I2 (de)
NO (1) NO322964B1 (de)
NZ (1) NZ314903A (de)
OA (1) OA10488A (de)
PA (1) PA8431001A1 (de)
PL (1) PL186949B1 (de)
PT (1) PT809996E (de)
RS (1) RS49533B (de)
RU (1) RU2180595C2 (de)
SA (1) SA97180030B1 (de)
SG (1) SG55314A1 (de)
SI (1) SI0809996T1 (de)
SK (1) SK284458B6 (de)
SV (1) SV1997000049A (de)
TJ (1) TJ328B (de)
TN (1) TNSN97091A1 (de)
TR (1) TR199700358A2 (de)
TW (1) TW517067B (de)
UA (1) UA56989C2 (de)
UY (1) UY24572A1 (de)
ZA (1) ZA974583B (de)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
DK0858343T3 (da) 1995-11-02 2004-05-10 Schering Corp Kontinuerlig lavdosis cytokininfusionsterapi
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
ATE297761T1 (de) * 1998-03-26 2005-07-15 Schering Corp Zubereitungen zur stabilisierung von peg- interferon alpha konjugaten
DK1075281T3 (da) * 1998-04-28 2005-01-03 Applied Research Systems Polyol-IFN-beta-konjugater
CZ300540B6 (cs) 1998-05-15 2009-06-10 Schering Corporation Farmaceutický prostredek obsahující ribavirin v kombinaci s interferonem alfa pro lécbu pacientu s chronickou infekcí hepatitidy C genotypu 1
JP3839667B2 (ja) * 1998-06-08 2006-11-01 エフ．ホフマン−ラ ロシュ アーゲー 慢性Ｃ型肝炎の処置のためのＰｅｇ−ＩＮＦ−アルファ及びリバビリンの使用
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
IL129299A0 (en) * 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
TWI271196B (en) * 1999-04-08 2007-01-21 Schering Corp CML therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
EP2025344B1 (de) 1999-04-08 2011-01-26 Schering Corporation Melanomtherapie
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
DE60139110D1 (de) 2000-01-10 2009-08-13 Maxygen Holdings Ltd G-csf konjugate
MXPA02007172A (es) * 2000-01-24 2002-12-13 Schering Corp Combinacion de temozolomida y alfa interferon pegilado para tratamiento de cancer.
EP1908477A3 (de) * 2000-01-24 2008-06-11 Schering Corporation Kombination aus Temozolomid und pegyliertem Interferon-alpha zur Krebsbehandlung
DK1257295T3 (da) 2000-02-11 2009-08-10 Bayer Healthcare Llc Faktor VII eller VIIA-lignende molekyler
US6476062B2 (en) 2000-03-30 2002-11-05 Schering Corporation Chemokine receptor antagonists
US6777387B2 (en) 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
US6756037B2 (en) 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
AU2001255495A1 (en) 2000-04-20 2001-11-07 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
DE60135393D1 (de) 2000-06-30 2008-09-25 Zymogenetics Inc Allelische Variante des Interferon-ähnlichen Proteins Zcyto21
ATE471956T1 (de) 2001-01-30 2010-07-15 Kyowa Hakko Kirin Co Ltd Verzweigte polyalkylenglykole
EP2080771A3 (de) 2001-02-27 2010-01-06 Maxygen Aps Neue Interferon-betaartige Moleküle
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
DE60315949T2 (de) * 2002-01-16 2008-06-12 Biocompatibles Uk Ltd., Farnham Polymerkonjugate
KR100888371B1 (ko) * 2002-01-17 2009-03-13 동아제약주식회사 가지 달린 고분자 유도체와 인터페론 결합체를 포함하는 항바이러스제
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
WO2004000366A1 (en) 2002-06-21 2003-12-31 Novo Nordisk Health Care Ag Pegylated factor vii glycoforms
RU2318004C2 (ru) 2002-07-24 2008-02-27 Ф.Хоффманн-Ля Рош Аг Добавки в виде полиалкиленгликолевой кислоты
AU2003260393B2 (en) * 2002-09-11 2009-10-01 Fresenius Kabi Deutschland Gmbh Method of producing hydroxyalkyl starch derivatives
EP1681303B1 (de) * 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylierte Polypeptide, besonders HASyliertes Erythropoietin
EP1400533A1 (de) * 2002-09-11 2004-03-24 Fresenius Kabi Deutschland GmbH Hasylierte Polypeptide, besonders hasyliertes Erythropoietin
ES2314238T3 (es) 2002-10-08 2009-03-16 Fresenius Kabi Deutschland Gmbh Conjugados de oligosacaridos farmaceuticamente activos.
US20040219131A1 (en) * 2002-11-18 2004-11-04 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
GB0301014D0 (en) * 2003-01-16 2003-02-19 Biocompatibles Ltd Conjugation reactions
CA2458085A1 (en) 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
CN1867581B (zh) 2003-10-10 2012-02-01 诺沃挪第克公司 Il-21衍生物
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
CA2553034A1 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human interferon polypeptides and their uses
CN100355784C (zh) * 2004-02-12 2007-12-19 江苏恒瑞医药股份有限公司 聚乙二醇修饰α－干扰素1b的制备方法
AU2005225513B2 (en) 2004-03-11 2012-01-12 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
WO2005113592A2 (en) 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
CA2568952C (en) 2004-06-18 2019-05-21 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US20060029573A1 (en) * 2004-06-30 2006-02-09 Chun Shen Pegylated interferon alpha-1b
US7632491B2 (en) 2004-08-12 2009-12-15 Schering Corporation Stable pegylated interferon formulation
EP1836314B1 (de) 2004-12-22 2012-01-25 Ambrx, Inc. Modifiziertes menschliches wachstumshormon
EP1861125A2 (de) * 2005-03-23 2007-12-05 Nektar Therapeutics Al, Corporation Konjugate eines hgh-teils und peg-derivate
CN101501068A (zh) 2005-05-18 2009-08-05 马克西根公司 改进的α-干扰素多肽
US8633300B2 (en) 2005-06-17 2014-01-21 Novo Nordisk Healthcare Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
CN101257925A (zh) * 2005-06-20 2008-09-03 派普根公司 人干扰素α类似物和干扰素τ的低毒长循环的嵌合体
JP4261531B2 (ja) 2005-09-06 2009-04-30 株式会社Ｎｒｌファーマ ラクトフェリン複合体及びその製造方法
CN101454461A (zh) 2005-11-16 2009-06-10 Ambrx公司 包括非天然氨基酸的方法和组合物
CN101002944B (zh) * 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
WO2007132882A1 (ja) 2006-05-16 2007-11-22 Tokyo Metropolitan Organization For Medical Research Hcv感染症を治療または予防するための医薬組成物
CN101484576A (zh) 2006-05-24 2009-07-15 诺沃-诺迪斯克保健股份有限公司 具有延长的体内半寿期的因子ix类似物
WO2008030558A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
SG174781A1 (en) 2006-09-08 2011-10-28 Ambrx Inc Hybrid suppressor trna for vertebrate cells
CN1966547B (zh) * 2006-11-06 2011-11-09 中国药科大学 双链结构的聚乙二醇衍生物的制备及其与药物分子的结合
CA2668478C (en) * 2006-11-07 2015-05-26 Dsm Ip Assets B.V. Carbamate, thiocarbamate or carbamide comprising a biomolecular moiety
KR101079993B1 (ko) 2006-11-17 2011-11-04 동아제약주식회사 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
CN101219219B (zh) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
JP5515224B2 (ja) 2007-02-28 2014-06-11 日油株式会社 多分岐鎖ポリオキシアルキレン誘導体
ES2385114T3 (es) 2007-03-30 2012-07-18 Ambrx, Inc. Polipéptidos de FGF-21 modificados y sus usos
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
DK2196475T3 (da) 2007-09-04 2012-09-17 Biosteed Gene Expression Tech Co Ltd Interferon alfa 2a, som er modificeret med polyethylenglycol, fremgangsmåde til syntese deraf samt anvendelse deraf
RU2485134C2 (ru) 2007-09-04 2013-06-20 Биостид Джене Експрешен Тек. Ко., Лтд. Интерферон альфа 2в, модифицированный полиэтиленгликолем, получение препарата и его применение
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
EP2070950A1 (de) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkylstärkederivate und deren Herstellungsverfahren
WO2009090056A2 (en) * 2008-01-18 2009-07-23 F. Hoffmann-La Roche Ag Purification of not-glycosylated polypeptides
US8906847B2 (en) * 2008-02-01 2014-12-09 Ascendis Pharma A/S Prodrug comprising a drug linker conjugate
NZ586947A (en) 2008-02-08 2012-11-30 Ambrx Inc Modified leptin polypeptides and their uses
PT2272875E (pt) 2008-04-03 2014-04-28 Biosteed Gene Expression Tech Co Ltd Hormona de crescimento modificada com polietilenoglicol de cadeia dupla, método de preparação e aplicação deste
HUE054585T2 (hu) * 2008-04-29 2021-09-28 Ascendis Pharma Endocrinology Div A/S Pegilezett rekombináns humán növekedési hormon vegyületek
TW201010692A (en) 2008-06-19 2010-03-16 Public Univ Corp Nagoya City Univ Pharmaceutical composition for treatment or prevention of hbv infection
JP5675606B2 (ja) 2008-07-08 2015-02-25 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム シグナル伝達性転写因子（ｓｔａｔ）の増殖及び活性化の新規の抑制剤
CN106928339A (zh) 2008-07-23 2017-07-07 Ambrx 公司 经修饰的牛g‑csf多肽和其用途
CN107022020A (zh) 2008-09-26 2017-08-08 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
BRPI0919031A2 (pt) 2008-09-26 2014-09-23 Ambrx Inc Micro-organismos e vacinas dependentes de replicação através do uso de aminoácidos não naturais
IT1399351B1 (it) 2009-06-16 2013-04-16 Fidia Farmaceutici Procedimento per la sintesi di coniugati di glicosamminoglicani (gag) con molecole biologicamente attive, coniugati polimerici e usi relativi
EP2459211A1 (de) 2009-07-31 2012-06-06 Medtronic, Inc. Kontinuierliche subkutane verabreichung von interferon an hepatitis-c-patienten
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
EP2805964A1 (de) 2009-12-21 2014-11-26 Ambrx, Inc. Modifizierte Rinder-Somatotropinpolypeptide und deren Verwendungen
MX2012006980A (es) 2009-12-21 2012-07-17 Ambrx Inc Polipeptidos de somatotropina porcina modificados y sus usos.
AU2011222883B2 (en) 2010-03-05 2016-05-26 Omeros Corporation Chimeric inhibitor molecules of complement activation
WO2011143274A1 (en) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
JP2013529627A (ja) 2010-06-24 2013-07-22 パンメド リミテッド ヒドロキシクロロキンまたはヒドロキシクロロキンおよび抗ウイルス剤の組合せを使用するｃ型肝炎ウイルス関連疾患の処置
RU2447083C1 (ru) * 2010-07-20 2012-04-10 Закрытое Акционерное Общество "Биокад" НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
EP2600898A1 (de) 2010-08-05 2013-06-12 F.Hoffmann-La Roche Ag Antivirales zytokinfusionsprotein mit mhc-antikörper
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
PT2605789T (pt) 2010-08-17 2019-09-03 Ambrx Inc Polipeptidos de relaxina modificados e suas utilizações
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
CN102229667A (zh) * 2011-06-03 2011-11-02 北京伟嘉人生物技术有限公司 一种聚乙二醇修饰的猪α-干扰素及其制备方法和应用
KR20140054009A (ko) 2011-07-01 2014-05-08 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신 융합 폴리펩타이드 및 그의 용도
SG10201606395XA (en) 2011-08-03 2016-09-29 Cytheris Hcv immunotherapy
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
WO2013143581A1 (en) 2012-03-28 2013-10-03 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in specific patient subgenotype sub-population
DK2859017T3 (da) 2012-06-08 2019-05-13 Sutro Biopharma Inc Antistoffer omfattrende stedsspecifikke ikke-naturlige aminosyrerester, fremgangsmåder til fremstilling heraf og fremgangsmåder til anvendelse heraf
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
EP4074728A1 (de) 2012-08-31 2022-10-19 Sutro Biopharma, Inc. Modifizierte peptide mit einer azidogruppe
EA022617B1 (ru) * 2013-03-28 2016-02-29 Илья Александрович МАРКОВ Монопегилированный интерферон-альфа разветвленной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа
EA023323B1 (ru) * 2013-03-28 2016-05-31 Илья Александрович МАРКОВ Разветвленный ацилазидный пегилирующий агент, способ его получения и способ получения пегилированного интерферона
EA021610B1 (ru) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Жидкое противовирусное лекарственное средство
ES2658039T3 (es) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
EP3055298B1 (de) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modifizierte aminosäuren mit funktionellen tetrazingruppen, verfahren zur herstellung und verfahren zu deren verwendung
EP2907512A1 (de) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Hemmer von MMP-12 als antivirale Wirkstoffe
RU2554761C1 (ru) * 2014-05-13 2015-06-27 Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" Противоэнтеровирусное и иммуностимулирующее средство
EP3209316A2 (de) 2014-10-24 2017-08-30 Bristol-Myers Squibb Company Modifizierte fgf-21-polypeptide und verwendungen davon
KR102540109B1 (ko) * 2014-11-06 2023-06-02 파마에센시아 코퍼레이션 Peg화된 인터페론의 투약 요법
SI3653227T1 (sl) 2014-11-18 2021-04-30 Ascendis Pharma Endocrinology Division A/S Nova polimerna predzdravila hGH
HRP20211734T8 (hr) 2014-11-21 2022-03-04 Ascendis Pharma Endocrinology Division A/S Dozni oblici dugodjelujućeg hormona rasta
AU2016349685A1 (en) 2015-11-03 2018-03-15 F. Hoffmann-La Roche Ag Combination therapy of an HBV capsid assembly inhibitor and an interferon
CN106749608B (zh) * 2015-11-18 2021-10-15 石药集团中奇制药技术（石家庄）有限公司 干扰素α缀合物
WO2018087345A1 (en) 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
RU2678332C1 (ru) 2017-09-08 2019-01-28 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения
CN116948006A (zh) 2018-09-11 2023-10-27 北京泰德制药股份有限公司 白介素-2多肽偶联物及其用途
US20220009986A1 (en) 2018-10-19 2022-01-13 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
US20220226488A1 (en) 2019-02-12 2022-07-21 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
CA3174114A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
TW202227449A (zh) 2020-08-20 2022-07-16 美商Ａｍｂｒｘ 公司 抗體－ｔｌｒ促效劑偶聯物、其方法及用途
US20220227805A1 (en) * 2020-12-23 2022-07-21 Jazz Pharmaceuticals Ireland Ltd. Methods of purifying charge-shielded fusion proteins
CA3213805A1 (en) 2021-04-03 2022-10-06 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
WO1984004745A1 (en) 1983-05-31 1984-12-06 Takeda Chemical Industries Ltd Novel polypeptides and their use
US4681848A (en) 1982-09-22 1987-07-21 Takeda Chemical Industries, Ltd. Novel peptide and use thereof
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3719046A1 (de) * 1987-06-06 1988-12-15 Basf Ag Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5145773A (en) * 1989-05-25 1992-09-08 Sloan-Kettering Institute For Cancer Research Method to detect sensitivity to alpha-interferon therapy
ES2085297T3 (es) * 1989-05-27 1996-06-01 Sumitomo Pharma Procedimiento para preparar derivados de poli(etilenglicol) y proteina modificada.
US5238915A (en) * 1991-02-08 1993-08-24 Wakunaga Seiyaku K.K. Aromatic composition and method for controlling aroma
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
GB9111967D0 (en) 1991-06-04 1991-07-24 Erba Carlo Spa 2,5'-nucleotide analogs as antiviral agents
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5711944A (en) * 1993-11-10 1998-01-27 Enzon, Inc. Interferon polymer conjugates
ES2159630T3 (es) * 1994-02-08 2001-10-16 Amgen Inc Sistema de administracion por via oral de proteinas g-csf quimicamente modificadas.
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
CA2458085A1 (en) * 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay

Also Published As

Publication number Publication date
DE69720320T2 (de) 2004-06-03
CY2005006I2 (el) 2009-11-04
CZ292775B6 (cs) 2003-12-17
CZ167997A3 (en) 1997-12-17
BG101540A (en) 1998-02-27
ES2110386T1 (es) 1998-02-16
BR9703421A (pt) 1998-09-15
EP0809996B1 (de) 2003-04-02
IL120902A0 (en) 1997-09-30
CO4950528A1 (es) 2000-09-01
UA56989C2 (uk) 2003-06-16
AR008378A1 (es) 2000-01-19
GR970300063T1 (en) 1998-01-30
UY24572A1 (es) 2000-12-29
DE10399018I1 (de) 2003-10-23
HRP970298B1 (en) 2003-08-31
LU91029I2 (fr) 2004-01-23
PL320251A1 (en) 1997-12-08
TJ328B (en) 2001-12-24
YU17597A (sh) 1999-07-28
KR100254097B1 (ko) 2000-05-01
NO322964B1 (no) 2006-12-18
SG55314A1 (en) 1998-12-21
IS4491A (is) 1997-12-01
MX9704012A (es) 1997-11-29
SK67397A3 (en) 1997-12-10
HU9700959D0 (en) 1997-07-28
CN1088721C (zh) 2002-08-07
NO972480L (no) 1997-12-01
ATE235920T1 (de) 2003-04-15
NO972480D0 (no) 1997-05-30
TNSN97091A1 (fr) 2005-03-15
DE69720320D1 (de) 2003-05-08
CY2433B1 (en) 2004-11-12
IS1988B (is) 2005-02-15
HU227992B1 (en) 2012-08-28
EP0809996A3 (de) 1999-04-14
MY117909A (en) 2004-08-30
JP2980569B2 (ja) 1999-11-22
MA24193A1 (fr) 1997-12-31
RS49533B (sr) 2006-12-15
TJ97000465A (en) 1998-12-25
CA2203480A1 (en) 1997-11-30
IL120902A (en) 2004-06-20
CN1167777A (zh) 1997-12-17
AU2372397A (en) 1997-12-04
JPH1067800A (ja) 1998-03-10
KR970074791A (ko) 1997-12-10
TR199700358A3 (tr) 1997-12-21
NL300127I1 (de) 2003-07-01
PL186949B1 (pl) 2004-04-30
US20040030101A1 (en) 2004-02-12
EP0809996A2 (de) 1997-12-03
TW517067B (en) 2003-01-11
CA2203480C (en) 2009-06-30
NL300127I2 (nl) 2003-09-01
ES2110386T3 (es) 2003-10-01
OA10488A (fr) 2002-04-11
SA97180030B1 (ar) 2005-11-12
SI0809996T1 (en) 2003-08-31
US7201897B2 (en) 2007-04-10
HRP970298A2 (en) 1998-04-30
EG24292A (en) 2009-01-08
ZA974583B (en) 1998-11-17
NZ314903A (en) 1998-10-28
BG62273B1 (bg) 1999-07-30
CY2005006I1 (el) 2009-11-04
HK1005225A1 (en) 1998-12-31
SV1997000049A (es) 1998-07-09
DK0809996T3 (da) 2003-07-21
AU725195B2 (en) 2000-10-05
SK284458B6 (sk) 2005-04-01
PA8431001A1 (es) 2000-05-24
TR199700358A2 (xx) 1997-12-21
RU2180595C2 (ru) 2002-03-20
HUP9700959A2 (hu) 1998-03-02
PT809996E (pt) 2003-06-30
HUP9700959A3 (en) 1998-03-30

Similar Documents

Publication Publication Date Title
DE809996T1 (de) Interferon-Konjugate
RU97108698A (ru) Конъюгаты интерферона
DE69317979T2 (de) PEG-Interferon-Konjugate
HK1038194A1 (en) Polyol-ifn-beta conjugates.
EP1570861A3 (de) Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und B-Mimetika
FR2596393B1 (fr) Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
ZA917484B (en) A process for the preparation of carnosic acid and the use of the acid for its anticarcinogenic and antiviral properties
GB8927546D0 (en) Process for the production of biologically active tgf-beta
CA2144312A1 (en) Unsaturated aliphatic dicarboxylic acids
JO2291B1 (en) Erythropoietin derivatives
DE860442T1 (de) Oligosaccharidoxazolines, Konjugate von Oligosacchariden und Verfahren zu ihrer Herstellung
HUT61661A (en) Process for producing pharmaceutical compositions for treating inflammatory gastrointestinal diseases
HUT54705A (en) Process for producing 11 beta-aryl-4-estrenes and pharmaceutical compositions comprising same
MY102918A (en) Purified antineoplaston fractions and methods of treating neoplastic disease.
DE69831928D1 (de) Von Willenbrand Faktor (vWF) enthaltende Zubereitung, verfahren zür Herstellung von vWF enthaltenden Zubereitungen und deren Verwendung
ZA934907B (en) 5,10-methylentetrahydrofolic acid-cyclodextrin inclusion compounds
CA2027133A1 (en) Inclusion complexes with silybinin, their preparation and pharmaceutical compositions containing them
EP0402062A3 (de) Verbindungen
HUT61024A (en) Process for producing 10(1-hydroxyethyl)-11-oxo-1-aza-tricyclo/7.2.0.0.3.8/undex-2-ene-2-carboxylic acid esters and pharmaceutical compositions comprising same as active ingredient
IT1080670B (it) Composizioni polimero/poliolo,processi per la loro preparazione e metodi per l'ottenimento da esse di prodotti poliuretanici
FR2543403B1 (fr) Nouveaux complexes d'inclusion de la cyclodextrine, leur preparation et leur utilisation comme insecticides
KR19990010187A (ko) 수용성 고분자-타크로리무스 접합체 화합물 및 그의 제조 방법
EP0127389A3 (en) N,n-diethyl-5-methyl-2h-1-benzothiopyrano-(4,3,2-cd)-indazole-2-ethanamine, compositions comprising the same and uses therefor
DE69529157T2 (de) Zusammensetzungen enthaltend filmbildende schweisshemmende polymere
ATA53290A (de) Sdk peptide, verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen